Allied Corp Completes Second German Medical Cannabis Delivery as Products Reach Pharmacies

October 1, 2025 - Allied Corp is pleased to announce that it has successfully completed a second German shipment of medical cannabis to one of its pharmaceutical distribution partners.

This delivery follows Allied’s first German shipment in July (click here) and marks another operational milestone in its expansion strategy, as the company’s products are now reaching pharmacies in Europe’s largest regulated medical cannabis market.

A Proven Supply Chain with Repeat Orders

Prior to this second order, Allied’s first German delivery in July saw strong uptake in pharmacies within weeks of landing in the country. Demand remains strong and the client, a licensed German pharmaceutical distributor, has already confirmed a third order, scheduled to be delivered in the next two months.

Allied’s flower was cultivated at its GACP-certified facility in Mesa de los Santos, Colombia, before being transferred to Blossom, an EU-GMP partner facility in Portugal, for API and primary processing. There, it underwent rigorous European Pharmacopeia (Table C) testing, covering microbial levels, pesticide residues, and heavy metals, and successfully passed all criteria – highlighting the repeatability of Allied’s compliant supply chain and the momentum building in Europe’s medical cannabis sector.

Colombian Advantage, European Standards

With European domestic cultivation often constrained by higher costs, distributors are increasingly turning to cost-efficient jurisdictions, such as Colombia, for value and premium ranges, where year-round cultivation, optimal climate, and lower production costs support competitive supply without compromising on quality.

Allied’s proven model – combining Colombian cultivation with European GMP processing – offers both cost-efficiency and compliance, positioning the company as a reliable long-term partner to meet Europe’s expanding medical cannabis demand.

With repeat deliveries now established into Germany, GACP certification secured and additional orders in the pipeline, Allied is building a proven track record of consistent, pharmaceutical-grade execution across Europe’s most advanced medical cannabis markets.

If you’re active in the space or want to exchange on the industry, we welcome the opportunity to connect.

Investor Relations : ir@allied.health

Website : https://www.allied.health

Disclaimer and Forward-Looking Statements:

No regulatory authority assumes responsibility for the accuracy or adequacy of this release.

This press release includes certain statements that may be deemed "forward-looking statements" under U.S. and Canadian securities laws. Forward-looking statements relate to Allied Corp.’s anticipated developments, strategic objectives, performance, and market opportunities. These include, but are not limited to, statements regarding Allied’s growth in Colombia, Kelowna, Nevada, and other key locations; intellectual property filings; joint development and manufacturing initiatives; and planned product introductions.

Forward-looking statements can often be identified by terms such as "anticipates," "believes," "expects," "intends," "plans," "will," "may," and similar expressions. These statements are based on current assumptions, projections, and management’s experience, but are subject to known and unknown risks and uncertainties that may cause actual results to differ materially. Notable risks include, but are not limited to, regulatory risks associated with the cannabis industry and market changes ; risks related to competition within the cannabis and medical industries; risks related to potential operational and logistical challenges; risks related to market demand; risks related to economic conditions impacting growth and profitability; risks related to potential delays or adverse changes in project locations or expansion plans; as well as other risks.

Though Allied endeavors to identify important factors that may impact actual outcomes, other unknown factors may also cause results to vary. The forward-looking statements contained in this news release are made as of the date of this news release. Except as required by law, the Company disclaims any intention and assumes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. Additionally, the Company undertakes no obligation to comment on the expectations of, or statements made, by third parties in respect of the matters discussed above.